---
title: Clinical trial to investigate the adherence of a new Rotigotine patch to the skin of patients with Parkinson’s disease
euct_id: 2025-521172-64-00
phase: Phase 4
status: Completed
sponsor: Luye Pharma Switzerland AG
canonical_url: "https://parkinsonspathways.com/trials/eu/2025-521172-64-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2025-521172-64-00"
ctis_last_updated: "2026-03-20T02:37:54.17543694"
source: EU Clinical Trials Information System (CTIS)
---
# Clinical trial to investigate the adherence of a new Rotigotine patch to the skin of patients with Parkinson’s disease

**EU CT Number:** [2025-521172-64-00](https://euclinicaltrials.eu/ctis-public/view/2025-521172-64-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Completed
- **Sponsor:** Luye Pharma Switzerland AG
- **Start Date:** 2025-10-15
- **Completion Date:** 2025-12-15
- **Conditions:** Parkinson's disease
- **Interventions:** ROT-TDS, Neupro 8 mg/24 h transdermal patch

## Member States

Trial is authorized in 1 member state: Germany.

## Sites (6)

- Praxis für Neurologie und Geriatrie, Ulm, Germany
- curiositas ad sanum Studien und Beratungs GmbH, Ebersberg, Germany
- Gertrudis-Klinik Parkinson-Zentrum GmbH, Leun-Biskirchen, Germany
- Praxis fr Neurologie und Psychiatrie Dr. Christian Oehlwein, Gera, Germany
- Parkinson-Klinik Ortenau GmbH & Co. KG, Wolfach, Germany
- Universitätsklinikum Ulm, Ulm, Germany

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease
Age groups: adults 18-64, elderly 65+
Sex: male, female
Includes a vulnerable population.

Period: Period 1
Once daily patch application of Test (ROT-TDS 12 mg/24 h)
Arms:
  - Arm 1: Reference-Test-Reference-Test
  - Arm 2: Test-Reference-Test-Reference

Period: Period 2
Once daily patch application of Reference (Neupro® 8 mg/24 h)
Arms:
  - Arm 1: Reference-Test-Reference-Test
  - Arm 2: Test-Reference-Test-Reference

Period: Period 3
Once daily patch application of Test (ROT-TDS 12 mg/24 h)
Arms:
  - Arm 1: Reference-Test-Reference-Test
  - Arm 2: Test-Reference-Test-Reference

Period: Period 4
Once daily patch application of Reference (Neupro® 8 mg/24 h)
Arms:
  - Arm 1: Reference-Test-Reference-Test
  - Arm 2: Test-Reference-Test-Reference
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2025-521172-64-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2025-521172-64-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2025-521172-64-00*